San Diego, CA -- (SBWIRE) -- 06/24/2014 -- An investigation on behalf of investors of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares over potential securities laws violations by Northwest Biotherapeutics and certain of its directors and officers in connection certain financial statements was announced .

Investors who purchased shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) concerning whether a series of statements by Northwest Biotherapeutics. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Northwest Biotherapeutics, Inc reported that its annual Total Revenue rose from $0.01 million in 2011 to $0.81 million in 2013. Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) grew from $3.21 per share in November 2013 to as high as $9.18 per share in March 2014, respectively $8.97 per share on June 18, 2014.

Then on June 19, 2014, an article was published that stated that "The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct.” Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) declined to $6.78 per share on June 19, 2014.

On June 20, 2014, NASDAQ:NWBO shares closed at $$7.44 per share.

Those who purchased shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com